Form 4: Zura Bio Director Arnout Ploos van Amstel Acquires Stock Options

Director Arnout Ploos van Amstel reports the acquisition of stock options in Zura Bio Ltd.

Summary

• Arnout Ploos van Amstel, a director of Zura Bio Ltd, filed a Form 4 disclosing a transaction involving derivative securities.
• On May 21, 2025, Mr. Ploos van Amstel acquired options to purchase 51,000 Class A Ordinary Shares at an exercise price of $1.03 per share.
• The options vest in twelve equal monthly installments starting from May 21, 2025, with any remaining unvested portion vesting before the next annual shareholder meeting, contingent on continued service.
• Mr. Ploos van Amstel also granted power of attorney to Kim Davis and Lindsey McClelland of Zura Bio Limited to execute and file SEC forms on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which can be seen as a positive sign of aligning director interests with shareholders, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

Form 4, Zura Bio, Stock Options, Director, Beneficial Ownership, Arnout Ploos van Amstel